Core Insights - NextCure, Inc. presented new preclinical data showing that NC605, an anti-Siglec-15 antibody, improves bone microarchitecture and reduces fracture incidence in a model of osteogenesis imperfecta (OI) compared to anti-sclerostin treatment [1][4] - OI is characterized by high bone turnover and fragility, with no current cure available; existing treatments increase bone density but compromise bone quality [2] - The study demonstrated that NP159, a surrogate for NC605, significantly enhanced bone mineral density and reduced fracture rates in OI mice [3] Company Overview - NextCure is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer patients who do not respond to existing treatments, utilizing differentiated mechanisms such as antibody-drug conjugates [6] - The company is seeking financial support to advance NC605 towards an Investigational New Drug submission within the next 12 to 18 months [5]